Bladder cancer: TICE, Connaught BCG yield similar RFS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • No significant difference in recurrence-free survival (RFS) between TICE and Connaught Bacillus Calmette-Guerin (BCG) strains used in combination with interferon in BCG-naïve and BCG-failure patients with nonmuscle-invasive bladder cancer.

Why this matters

  • There has been limited investigation on substrain comparative efficacy, though differences in phenotypes and antigenicity have been reported.

Key results

  • BCG naïve patients who received TICE BCG had RFS rates of 80% at 3 mo, 64% at 1 y, and 54% at 2 y. 
  • Connaught BCG patients had RFS rates of 83%, 70%, and 65%, respectively. 
  • Univariable analysis found duration of disease >2 y (P=.04), multifocal tumors (P=.04), tumor size >5 cm vs <0.5 cm (P<0.01), and TICE BCG (P=.05) were associated with increased risk for recurrence. 
  • After controlling for duration of disease, tumor focality, and tumor size, strain was no longer an independent risk factor (P=.28). 
  • BCG-failure patients who received TICE BCG had 3-mo, 1-y, and 2-y RFS rates of 79%, 53%, and 44%, respectively. 
  • Connaught BCG patients had rates of 81%, 58%, and 47%, respectively. 
  • BCG strain had no significant prognostic value for recurrence (P=.53).

Study design

  • Post hoc analysis of a phase 2 study (N=901). 
  • Funding: None disclosed.

Limitations

  • Post hoc analysis. 
  • Nonrandomized.